| Qiu, Lugui |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06319456: A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. |
|
|
| Recruiting | 3 | 344 | RoW | Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine, Cyclophosphamide，CTX, Rituximab, Chlorambucil | Ascentage Pharma Group Inc. | CLL/SLL | 08/27 | 08/28 | | |
D822BC00001, NCT04075292: Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 3 | 155 | RoW | Acalabrutinib, Rituximab, Chlorambucil | AstraZeneca | Untreated Chronic Lymphocytic Leukemia | 01/24 | 03/25 | | |
|
|
|
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT04453345: TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL |
|
|
| Recruiting | 2/3 | 42 | RoW | thalidomide + prednisone + methotrexate, TPM regimen | Institute of Hematology & Blood Diseases Hospital, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital of Guangxi Medical University, Henan Cancer Hospital, First Hospital of Jilin University, Central South University, Tianjin First Central Hospital | T-LGL Leukemia, Clpd-Nk | 05/23 | 05/25 | | |
NCT03860038: TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 2 | 113 | RoW | TJ202 and Dexamethasone | TJ Biopharma Co., Ltd. | Multiple Myeloma in Relapse, Refractory Multiple Myeloma | 01/23 | 12/24 | | |
NCT06158269: DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma |
|
|
| Recruiting | 2 | 40 | RoW | DVRd | Institute of Hematology & Blood Diseases Hospital, China | Multiple Myeloma | 12/26 | 12/27 | | |
NCT06244368: GVM±R in Patients With Relapsed or Refractory Aggressive NHL. |
|
|
| Recruiting | 2 | 115 | RoW | GVM±R regimen | Qiu Lugui | Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | 06/25 | 06/27 | | |
NCT06539195: DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) |
|
|
| Recruiting | 2 | 180 | RoW | DZD8586 | Dizal Pharmaceuticals | Diffuse Large B Cell Lymphoma | 10/27 | 04/28 | | |
| Recruiting | 2 | 120 | RoW | Etoposide, Cyclophosphamide, Mecapegfilgrastim, day 2, Mecapegfilgrastim, day 5 | Qiu Lugui, Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Multiple Myeloma, Lymphoma | 03/24 | 09/24 | | |
NCT06489808: Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL |
|
|
| Recruiting | 2 | 89 | RoW | Linperlisib, Rituximab, Gemcitabine, Oxaliplatin, Ifosfamide, Carboplatin, Etoposide, Dexamethasone, Cisplatin, Ara-C, Vinorelbine, Mitoxantrone hydrochloride liposome | Institute of Hematology & Blood Diseases Hospital, China | Relapsed/Refractory Large B-Cell Lymphoma | 12/26 | 05/27 | | |
| Not yet recruiting | 2 | 66 | NA | Sonrotoclax, BGB-11417, Zanubrutinib, BGB- 3111 | Institute of Hematology & Blood Diseases Hospital, China | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 02/30 | 07/30 | | |
ZGR, NCT06504199: Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 39 | RoW | Obinutuzumab, Zanubrutinib, Lenalidomide, Cytarabine, CAR-T | Institute of Hematology & Blood Diseases Hospital, China | Mantle Cell Lymphoma | 12/26 | 12/28 | | |
NCT06530576: Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia |
|
|
| Recruiting | 2 | 48 | RoW | Thalidomide and methotrexate | Institute of Hematology & Blood Diseases Hospital, China | T-LGL Leukemia, NK-LGL Leukemia | 07/26 | 07/27 | | |
NCT06530550: PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas |
|
|
| Recruiting | 2 | 51 | RoW | PI3K inhibitor | Institute of Hematology & Blood Diseases Hospital, China | Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia | 07/26 | 07/28 | | |
NCT06716658: JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/refractory Indolent T/NK-cell Lymphomas |
|
|
| Recruiting | 2 | 48 | RoW | JAK1 Inhibitor | Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Xijing hospital of air force Medical University, First Affiliated Hospital of Jilin University, The First Affiliated Hospital of Nanchang University, Henan Cancer Hospital, Second Xiangya Hospital of Central South University, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China | Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia, Cutaneous T Cell Lymphoma, Cutaneous T Cell Lymphoma (CTCL), Large Granular Lymphocyte Leukemia, Large Granular Lymphocytic Leukemia, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Mycosis Fungoides | 11/26 | 11/28 | | |
| Recruiting | 2 | 42 | RoW | Zanubrutinib, Bendamustine and Rituximab | Institute of Hematology & Blood Diseases Hospital, China | Waldenstrom Macroglobulinemia | 03/25 | 12/25 | | |
FUMANBA-1, NCT05066646: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 132 | RoW | CT103A | Nanjing IASO Biotherapeutics Co.,Ltd | Multiple Myeloma | 10/22 | 06/24 | | |
| Recruiting | 1/2 | 154 | RoW | MBS314 Injection | Beijing Mabworks Biotech Co., Ltd. | Relapsed or Refractory Multiple Myeloma | 02/26 | 03/28 | | |
NCT06594640: R-CMOP in Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 1/2 | 108 | RoW | Mitoxantrone Hydrochloride Liposome, Rituximab (R), Cyclophosphamide (CTX), Vincristin, Prednisolone | Qiu Lugui | Diffuse Large B-cell Lymphoma | 06/26 | 07/27 | | |
NCT05521802: A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 92 | RoW | B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell | Cellular Biomedicine Group Ltd. | Multiple Myeloma | 07/24 | 07/37 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
| Completed | 1/2 | 15 | Europe, Canada, US, RoW | Modakafusp Alfa, TAK-573, Daratumumab | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 05/24 | 05/24 | | |
NCT05944978: A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies |
|
|
| Recruiting | 1/2 | 40 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd. | Relapsed/Refractory Chronic Lymphocytic Leukemia | 08/25 | 08/25 | | |
ELEVATION, NCT05800977: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma |
|
|
| Recruiting | 1/2 | 112 | RoW | Prizloncabtagene autoleucel, C-CAR039 | Shanghai AbelZeta Ltd. | Relapsed/Refractory Large B-Cell Lymphoma | 10/25 | 12/27 | | |
| Recruiting | 1 | 58 | RoW | YY-20394 | Shanghai YingLi Pharmaceutical Co. Ltd. | Relapsed or Refractory Peripheral T-Cell Lymphoma | 06/21 | 12/21 | | |
NCT04250324: Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma |
|
|
| Recruiting | 1 | 21 | RoW | BZ019 | Shanghai Cell Therapy Group Co.,Ltd, Institute of Hematology & Blood Diseases Hospital, Tianjin Medical University Cancer Institute and Hospital | Large B-cell Lymphoma | 08/22 | 12/22 | | |
NCT05011097: A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 75 | RoW | Y150 | Wuhan YZY Biopharma Co., Ltd. | Relapsed or Refractory Multiple Myeloma | 07/23 | 12/24 | | |
NCT03664297: Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor |
|
|
| Active, not recruiting | 1 | 86 | RoW | SHR1459, No other intervention | Jiangsu HengRui Medicine Co., Ltd. | Mature B Cell Neoplasms | 12/23 | 12/24 | | |
NCT05758610: A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients |
|
|
| Recruiting | 1 | 60 | RoW | ETH-155008, Study drug | Shengke Pharmaceuticals (Jiangsu) Limited, China | NHL, Adult, AML, Adult Recurrent | 12/25 | 06/26 | | |
NCT05318963: Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma |
|
|
| Recruiting | 1 | 34 | RoW | LCAR-AIO cells product | Qiu Lugui, Nanjing Legend Biotech Co. | B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | 06/24 | 06/26 | | |
| Recruiting | 1 | 116 | RoW | TQB3820 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hematological Malignancies | 08/24 | 12/24 | | |
NCT06615193: A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor |
|
|
| Recruiting | 1 | 111 | RoW | HDM2005 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy | 06/26 | 02/28 | | |
| Recruiting | 1 | 191 | RoW | ICP-248, ICP-248+Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/25 | 10/26 | | |
NCT05920876: A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 100 | RoW | QLS32015, A Humanized GPRC5D x CD3 Bispecific Antibody | Qilu Pharmaceutical Co., Ltd. | Relapsed or Refractory Multiple Myeloma | 12/24 | 08/25 | | |
NCT05913804: YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma |
|
|
| Not yet recruiting | 1 | 8 | RoW | YTS104 Cells injection | Institute of Hematology & Blood Diseases Hospital, China Immunotech (Beijing) Biotechnology Co., Ltd. | Relapsed or Refractory Multiple Myeloma | 12/25 | 12/25 | | |
NCT06047197: Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 1 | 25 | RoW | RC19D2 cell injection | Beijing Yongtai Ruike Biotechnology Company Ltd | Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | 09/26 | 12/26 | | |
NCT05693012: Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma |
|
|
| Recruiting | N/A | 398 | RoW | cfDNA methylation assessment | Qiu Lugui, Guangzhou Burning Rock Dx Co., Ltd. | Multiple Myeloma | 12/23 | 12/24 | | |
| Xiao, Zhijian |
CMML1-2, NCT06647862: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia |
|
|
| Recruiting | 3 | 170 | RoW | IMM01, Timdarpacept, Azacitidine, Placebo | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Chronic Myelomonocytic Leukemia | 10/26 | 10/29 | | |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
| Recruiting | 2 | 105 | RoW | TQ05105 tablets, Hydroxycarbamide tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Moderate and High Risk Myelofibrosis | 03/23 | 09/23 | | |
AK117-205, NCT06196203: A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes |
|
|
| Recruiting | 2 | 90 | US, RoW | AK117, Placebo, Azacitidine | Akeso | Higher-risk Myelodysplastic Syndromes | 01/26 | 06/26 | | |
NCT06457425: Flunotinib Maleate Phase II Intermediate-High Risk Bone Fiber Clinical Trial |
|
|
| Recruiting | 2 | 75 | RoW | Flonoltinib 50mg, Flonoltinib 100mg, Ruxolitinib | Chengdu Zenitar Biomedical Technology Co., Ltd | MF,PMF,PPV-MF,PET-MF | 05/26 | 07/26 | | |
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
|
|
| Completed | 1/2 | 105 | RoW | TJ011133 | TJ Biopharma Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) | 12/23 | 12/23 | | |
|
|
HATCH, NCT04691141: A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) |
|
|
| Terminated | 1/2 | 15 | RoW | ATG-016 | Shanghai Antengene Corporation Limited | Myelodysplastic Syndrome | 09/23 | 09/23 | | |
| Recruiting | 1b | 32 | RoW | BC3402, Azacitidine | Biocity Biopharmaceutics Co., Ltd. | Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 03/25 | 12/25 | | |
NCT04485065: Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS |
|
|
| Suspended | 1 | 120 | RoW | IBI188+azacitidine | Innovent Biologics (Suzhou) Co. Ltd. | Myelodysplastic Syndromes | 12/23 | 08/24 | | |
| Wang, Tingyu |
BDHCLL001, NCT03980002: A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL |
|
|
| Recruiting | 2 | 50 | RoW | FCR and Ibrutinib, BR and Ibrutinib, Ibrutinib and Thalidomide | Institute of Hematology & Blood Diseases Hospital | Chronic Lymphocytic Leukemia | 12/22 | 12/27 | | |
NCT05147467: Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 2 | 75 | RoW | APG2575 | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 09/24 | 12/24 | | |
| Not yet recruiting | 2 | 30 | RoW | R-EPOCH in Combination With Ibrutinib | Institute of Hematology & Blood Diseases Hospital, Xian-Janssen Pharmaceutical Ltd. | Richter Transformation | 08/24 | 08/25 | | |
| Jiao, Ying |
| No trials found |
